Therapeutic potential of endothelin receptor modulators: Lessons from human clinical trials

Expert Opinion on Therapeutic Targets

Volumn 13, Issue 9, 2009, Pages 1069-1084

  Aubert, John David ^a   Juillerat Jeanneret, Lucienne ^b  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY INSTITUTE OF PATHOLOGY   (Switzerland)

Author keywords

Cancer; Cardiovascular diseases; Clinical trials; Endothelin receptor antagonists; Fibrosis; Pulmonary arterial hypertension; Vasospasm

Indexed keywords

AMBRISENTAN; ATRASENTAN; AVOSENTAN; BONE MORPHOGENETIC PROTEIN RECEPTOR 2; BOSENTAN; CLAZOSENTAN; CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); CYCLOSPORIN; DARUSENTAN; ENDOTHELIN 1; ENDOTHELIN 2; ENDOTHELIN 3; ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; ENDOTHELIN CONVERTING ENZYME; ENDOTHELIN CONVERTING ENZYME INHIBITOR; ENDOTHELIN RECEPTOR ANTAGONIST; ENRASENTAN; LU 208075; N (2,6 DIMETHYLPIPERIDINOCARBONYL) 4 METHYLLEUCYL DEXTRO (1 METHOXYCARBONYLTRYPTOPHANYL) DEXTRO NORLEUCINE; N (3 METHOXY 5 METHYL 2 PYRAZINYL) 2 [4 (1,3,4 OXADIAZOL 2 YL)PHENYL] 3 PYRIDINESULFONAMIDE; NITRIC OXIDE; PLACEBO; SITAXSENTAN; TACROLIMUS; TAK 044; TEZOSENTAN; UNCLASSIFIED DRUG;

ANTIHYPERTENSIVE ACTIVITY; ANTINEOPLASTIC ACTIVITY; BRAIN VASOSPASM; CARDIOVASCULAR AUTOREGULATION; CARDIOVASCULAR EFFECT; CLINICAL TRIAL; COLON CANCER; CONGESTIVE HEART FAILURE; DIABETIC NEPHROPATHY; DRUG EFFICACY; FIBROSIS; GLIOBLASTOMA; GLIOMA; HEART FAILURE; HUMAN; HYPERTENSION; KIDNEY CANCER; MELANOMA; NEPHROTOXICITY; NONHUMAN; OUTCOME ASSESSMENT; OVARY CANCER; PROSTATE CANCER; PULMONARY HYPERTENSION; RECEPTOR AFFINITY; REVIEW; VASOSPASM;

ANIMALS; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; ENDOTHELINS; HUMANS; HYPERTENSION, PULMONARY; NEOPLASMS; RECEPTORS, ENDOTHELIN;

EID: 68549099894     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728220903074570     Document Type: Review

References (100)

1. Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1998;332:411-415 •• The initial publication describing the discovery of endothelin-1.
2. Xu D, Emoto N, Giaid A, et al. ECE-1: a membrane-bound metalloprotease that catalyzes the proteolytic activation of big endothelin-1. Cell 1994;78:473-485 (Pubitemid 24250811)
3. Azarani A, Boileau G, Crine P. Recombinant human endothelin-converting enzyme ECE-1b is located in an intracellular compartment when expressed in polarized Madin-Darby canine kidney cells. Biochem J 1998;333:439-448 (Pubitemid 28379548)
4. Muller L, Barrett A, Etienne E, et al. Heterodimerization of endothelin-converting-enzyme-1 isoforms regulates the subcellular distribution of this metalloprotease. J Biol Chem 2003;278:545-555 (Pubitemid 36043608)
5. Turner AJ, Barnes K, Schweizer A, et al. Isoforms of endothelin- converting enzyme: why and where? TIPS 1998;19:483-486
6. Valdenaire O, Lepailleur-Enouf D, Egidy G, et al. A fourth isoform of endothelin-converting enzyme (ECE-1) is generated from an additional promoter: molecular cloning and characterization. Eur J Biochem 1999;264:341-349 (Pubitemid 29424437)
7. Berger Y, Dehmlow H, Blum-Kaelin D, et al. Endothelin-converting-enzyme-1 inhibition and growth of human glioblastoma cells. J Med Chem 2005;48:483-498 (Pubitemid 40139791)
8. Russell FD, Coppell AL, Davenport AP. In vitro enzymatic processing of radiolabelled big ET-1 in human kidney. Biochem Pharm 1998;55:697-701
9. Hayasaki-Kajiwara Y, Naya N, Shimamura T, et al. Endothelin generating pathway through endothelin1-31 in human cultured bronchial smooth muscle cells. Br J Pharmacol 1999;127:1415-1421 (Pubitemid 29358942)
10. Lazarini F, Strosberg AD, Couraud PO, et al. Coupling of ETB endothelin receptor to mitogen-activated protein kinase stimulation and DNA synthesis in primary cultures of rat astrocytes. J Neurochem 1996;66:459-465 (Pubitemid 26036679)
11. Leach K, Turner D, Zhang W, et al. Endothelin-1 stimulates c-fos mRNA expression in C6 glioma cells via MAP kinase pathway. Peptides 1999;20:907-914 (Pubitemid 29418024)
12. Sasaki Y, Hori S, Oda K, et al. Both ETA and ETB receptors are involved in mitogen-activated protein kinase activation and DNA synthesis of astrocytes: study using ETB receptor-deficient rats (aganglionosis rats). Eur J Neurosci 1998;10:2984-2993 (Pubitemid 29073971)
13. Bremnes T, Paasche JD, Mehlum A, et al. Regulation of intracellular trafficking pathways of the endothelin receptors. J Biol Chem 2000;275:17596-17604 (Pubitemid 30430805)
14. Ishikawa K, Ihara M, Noguchi K, et al. Biochemical and pharmacological profile of a potent and selective endothelin B-receptor antagonist, BQ788. Proc Natl Acad Sci USA 1994;91:4892-4896 (Pubitemid 24177756)
15. Jimeno A, Carducci M. Atrasentan: targeting the endothelin axis in prostate cancer. Expert Opin Invest Drugs 2004;13:1631-1640 (Pubitemid 39625146)
16. Jimeno A, Carducci M. Atrasentan: a novel and rationally designed therapeutic alternative in the management of cancer. Expert Rev Anticancer Ther 2005;5:419-427 (Pubitemid 40894976)
17. Liu G. Recent advances in endothelin antagonism. Ann Rev Med Chem 2000;8:73-82
18. Morris CD, Rose A, Curwen J, et al. Specific inhibition of the endothelin A receptor with ZD4054: clinical and pre-clinical evidence. Br J Cancer 2005;92:2148-2152 (Pubitemid 40966249)
19. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346:896-903 •• Establishment of the clinical interest in endothelin receptor antagonism for the first clinical indication and clinical use of an antagonist.
20. Bourgeois C, Robert B, Rebourcet R, et al. Endothelin-1 and ETA receptor expression in vascular smooth muscle cells from human placenta: a new ETA receptor messenger ribonucleic acid is generated by alternative splicing of exon 3. J Clin Endocrinol Metab 1997;82:3116-3123 (Pubitemid 27385685)
21. Elshourbagy NA, Adamou JE, Gagnon AW, et al. Molecular characterization of a novel human endothelin receptor splice variant. J Biol Chem 2000;271:25300-25307
22. Imamura F, Arimoto I, Fujiyoshi Y, et al. W276 mutation in the endothelin receptor subtype B impairs Gq coupling but not Gi or Go coupling. Biochem 2000;39:686-692 (Pubitemid 30065037)
23. Lo KW, Tsang YS, Kwong J, et al. Promoter hypermethylation of the EDNRB gene in nasopharyngeal carcinoma. Int J Cancer 2002;98:651-655 (Pubitemid 34225614)
24. Miyamoto Y, Yoshimasa T, Arai H, et al. Alternative RNA splicing of the human endothelin-A receptor generates multiple transcripts. Biochem J 1996;313:795-801 (Pubitemid 26050810)
25. Nambi P, Wu HL, Ye D, et al. Characterization of a novel porcine endothelin B receptor splice variant. J Pharm Exp Ther 2000;292:247-253 (Pubitemid 30026377)
26. Pao MM, Tsutsumi M, Liang G, et al. The endothelin receptor B (EDNRB) promoter displays heterogeneous, site specific methylation patterns in normal and tumor cells. Hum Mol Gen 2001;10:903-910 (Pubitemid 32401406)
27. Shyamala V, Moulthrop TH, Stratton-Thomas J, et al. Two distinct human endothelin B receptors generated by alternative splicing form a single gene. Cell Mol Biol Res 1994;40:285-296
28. Tsutsumi M, Liang G, Jones PA. Novel endothelin B receptor transcripts with the potential of generating a new receptor. Gene 1999;228:43-49 (Pubitemid 29136685)
29. Zhang YF, Jeffery S, Burchill SA, et al. Truncated human endothelin receptor A produced by alternative splicing and its expression in melanoma. Br J Cancer 1998;78:1141-1146 (Pubitemid 28479140)
30. Wenzel RR, Noll G, Luscher TF. Endothelin receptor antagonists inhibit endothelin in human skin microcirculation. Hypertension 1994;(23):581-586 (Pubitemid 24129351)
31. Kiowski W, Lüscher TF, Linder L, et al. Endothelin-1-induced vasoconstriction in humans. Reversal by calcium channel blockade but not nitrovasodilators or endothelium-derived relaxing factor. Circulation 1991;83:469-475
32. Cardillo C, Kilcoyne CM, Waclawiw M, et al. Role of endothelin in the increased vascular tone of patients with essential hypertension. Hypertension 1999;33:753-758 (Pubitemid 29091660)
33. Goddard J, Johnston NR, Hand MF, et al. Endothelin-A receptor antagonism reduces blood pressure and increases renal blood flow in hypertensive patients with chronic renal failure: a comparison of selective and combined endothelin receptor blockade. Circulation 2004;109:1186-1193 (Pubitemid 38332625)
34. Cowburn PJ, Cleland JG, McDonagh TA, et al. Comparison of selective ETA and ETB receptor antagonists in patients with chronic heart failure. Eur J Heart Fail 2005;7:37-42 (Pubitemid 40092489)
35. Battistini B, Berthiaume N, Kelland NF, et al. Profile of past and current clinical trials involving endothelin receptor antagonists: the novel "-sentan" class of drug. Exp Biol Med 2006;231:653-695 •• An extensive review of the human clinical trials of ET receptor(s) antagonists.
36. Naito S, Shimizu S, Maeda S, et al. Ets-1 is an early response gene activated by ET-1 and PDGF-BB in vascular smooth muscle cells. Am J Physiol 1998;274:C472-80 (Pubitemid 28140792)
37. Salani D, Taraboletti G, Rosano L, et al. Endothelin-1 induces an angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Am J Pathol 2000;157:1703-1711 (Pubitemid 30943227)
38. Sutsch G, Kiowski W, Yan XW, et al. Short-term oral endothelin-receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure. Circulation 1998;98:2262-2268 (Pubitemid 28533844)
39. Giverz MM, Colucci WS, Lejemtel TH, et al. Acute endothelin A receptor blockade causes selective pulmonary vasodilatation in patients with chronic heart failure. Circulation 2000;101:2922-2927 (Pubitemid 30415882)
40. Mylona P, Cleland JG. Update of REACH-1 and MERIT-HF clinical trials in heart failure. Cardio.net Editorial Team. Eur J Heart Failure 2000;1:197-200
41. Teerlink JR. Recent heart failure trials of neurohormonal modulation (OVERTURE and ENABLE): approaching the asymptote of efficacy ? J Card Fail 2002;8:124-127
42. Abrahams W. Progress in clinical trials: ENCOR. Clin Cardiol 2001;24:481-483
43. Anand I, McMurray J, Cohn JN, et al. Long-term effects of darusentan on left ventricular remodeling and clinical outcomes in the endothelin A receptor antagonist trial in heart failure (EARTH): randomized, double-blind, placebo-controlled trial. Lancet 2004;364:347-354
44. Kelland NF, Webb DJ. Clinical trials of endothelin antagonists in heart failure: a question of dose? Exp Biol Med 2006;231:696-699
45. Sasser JM, Sullivan JC, Hobbs JL, et al. Endothelin A receptor blockade reduces diabetic renal injury via an anti-inflammatory mechanism. J Am Soc Nephrol 2007;18:143-154
46. Dhaun N, Ferro CJ, Davenport AP, et al. Haemodynamic and renal effects of endothelin receptor antagonism in patients with chronic renal disease. Nephrol Dial Transplant 2007;22:3228-3234 (Pubitemid 350202548)
47. Wenzel RR, Littke T, Kuranoff S, et al. SPP301 (Avosentan) Endothelin Antagonist Evaluation in Diabetic Nephropathy Study Investigators. Avosentan reduces albumin excretion in diabetics with macroalbuminuria. J Am Soc Nephrol 2009;20:655-664
48. Smolander J, Vogt B, Maillard M, et al. Dose-dependent acute and sustained renal effects of the endothelin receptor antagonist avosentan in healthy subjects. Clin Pharmacol Ther 2009;85(6):628-634
49. Giaid A, Yanagisawa M, Langleben D, et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 1993;328:1732-1739 (Pubitemid 23170122)
50. Eddahibi S, Raffestin B, Clozel M, et al. Protection from pulmonary hypertension with an orally active endothelin receptor antagonist in hypoxic rats. Am J Physiol 1995;268:H828-35
51. Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomized placebo-controlled study. Lancet 2001;358:1119-1123 •• Establishment of the clinical interest in endothelin receptor antagonism for the first clinical indication and clinical use of an antagonist. (Pubitemid 32971843)
52. Hoeper MM, Halank M, Marx C, et al. Bosentan therapy for portopulmonary hypertension. Eur Respir J 2005;25:502-508
53. Hoeper MM, Kramm T, Wilkens H, et al. Bosentan therapy for inoperable chronic thromboembolic pulmonary hypertension. Chest 2005;128:2363-2367 (Pubitemid 41507580)
54. Hughes RJ, Jais X, Bonderman D, et al. The efficacy of bosentan in inoperable chronic thromboembolic pulmonary hypertension: a 1-year follow-up study. Eur Respir J 2006;28:138-143 (Pubitemid 44914271)
55. Sitbon O, Beghetti M, Petit J, et al. Bosentan for the treatment of pulmonary arterial hypertension associated with congenital heart defects. Eur J Clin Invest 2006;36:25-31 (Pubitemid 44179778)
56. Stolz D, Rasch H, Linka A, et al. A randomized, controlled trial of bosentan in severe COPD. Eur Respir J 2008;32:619-628
57. Barst RJ, Langleben D, Frost A, et al. Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med 2004;169:441-447 (Pubitemid 38187114)
58. Galie N, Badesch D, Oudiz R, et al. Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2005;46:529-535 (Pubitemid 41040298)
59. Macchia A, Marchioli R, Marfisi R, et al. A meta-analysis of trials of pulmonary hypertension: a clinical condition looking for drugs and research methodology. Am Heart J 2007;153:1037-1047 (Pubitemid 46809838)
60. Sauvageau S, Thorin E, Caron A, et al. Endothelin-1-induced pulmonary vasoreactivity is regulated by ETA and ETB receptor interactions. J Vasc Res 2007;44:375-381 (Pubitemid 47312658)
61. Porter KE, Olojugba DH, Masood I, et al. Endothelin-B receptors mediate intimal hyperplasia in an organ culture of human saphenous vein. J Vasc Surg 1998;28:695-701 (Pubitemid 28481225)
62. Galiè N, Manes A, Negro L, et al. A meta-analysis of randomized controlled trials in pulmonary arterial hypertension. Eur Heart J 2009;30:394-403
63. Vajkoczy P, Meyer B, Weidauer S, et al. Clazosentan (AXV-034343), a selective endothelin A receptor antagonist, in the prevention of cerebral vasospasm following severe aneurismal subarachnoid hemorrhage: results of a randomized, double-blind, placebo-controlled, multicenter Phase IIa study. J Neurochir 2005;103:9-17 (Pubitemid 43193928)
64. Shaw MD, Vermeulen M, Murray GD, et al. Efficacy and safety of the endothelin receptor antagonist TAK-044 in treating subarchnoid hemorrhage. J Neurosurg 2000;93:992-997
65. McDonald RL, Kassel NF, Mayer S, et al. Clazosentan to overcome neurological ischemia and infarction occurring after subarachnoid hemorrhage (CONSCIOUS-1). Randomized, double-blind, placebo-controlled phase 2 dose-finding trial. Stroke 2008;39:3015-3021
66. Nelson J, Bagnato A, Battistini B, et al. The endothelin axis: emerging role in cancer. Nat Rev Cancer 2003;3:110-116 • A review of the potential role of the endothelin axis in cancer. (Pubitemid 37328878)
67. Egidy G, Juillerat-Jeanneret L, Jeannin JF, et al. Modulation of human colon tumor-stromal interactions by the endothelin system. Am J Pathol 2000;157:1863-1874
68. Egidy G, Peduto Eberl L, Valdenaire O, et al. The endothelin system in human glioblastoma. Lab Invest 2000;80:1681-1689
69. Peduto Eberl L, Valdenaire O, SaintGiorgio V, et al. Endothelin receptor blockade potentiates FasL-induced apoptosis in rat colon carcinoma cells. Int J Cancer 2000;86:182-187 (Pubitemid 30180812)
70. Peduto Eberl L, Bovey R, Juillerat-Jeanneret L. Endothelin-receptor antagonists are pro-apoptotic and anti-proliferative in human colon cancer cells. Br J Cancer 2003;88:788-795 (Pubitemid 36411461)
71. Patel KV, Schrey MP. Endothelins in breast cancer. Cancer Treat Res 1996;83:369-394
72. Douglas ML, Richardson MM, Nicol DL. Endothelin axis expression is markedly different in the two main subtypes of renal cell carcinoma. Cancer 2004;100:2118-2124
73. Grant K, Loizidou M, Taylor I. Endothelin-1: a multifunctional molecule in cancer. Br J Cancer 2003;88:163-166
74. Grimshaw MJ. Endothelins in breast tumour cell invasion. Cancer Lett 2005;222:129-138
75. Kusuhara M, Yamaguchi K, Nagasaki N, et al. Production of endothelin in human cancer cell lines. Cancer Res 1990;50:3257-3261 (Pubitemid 20190127)
76. Bagnato A, Natali PG. Endothelin receptors as novel targets in tumor therapy. J Translat Med 2004;2:16-24 (Pubitemid 39130356)
77. Berger Y, Chapuis Bernasconi C, Juillerat-Jeanneret L. Targeting the endothelin axis in human melanoma: combination of endothelin receptor antagonism and alkylating agents. Exp Biol Med 2006;231:111-119 (Pubitemid 43845588)
78. Lahav R, Heffner G, Patterson PH. An endothelin receptor B antagonist inhibits growth and induces cell death in human melanoma cells in vitro and in vivo. Proc Nat Acad Sci USA 1999;96:11496-11500 (Pubitemid 29487409)
79. Kefford R, McNeil Beith J, Van Hazel GA, et al. A Phase II study of Bosentan, a dual endothelin receptor antagonist, as monotherapy in patients with stage IV metastatic melanoma. Invest New Drugs 2007;25:247-252 (Pubitemid 46774695)
80. Nelson JB, Love W, Chin JL, et al. Phase 3, randomized, controlled trial of atrasentan in patients with nonmetaststic hormone-refractory prostate cancer. Cancer 2008;113:2478-2487
81. Chiappori AA, Haura E, Rodriguet FA, et al. Phase I/II of Atrasentan, an endothelin A receptor antagonist, in combination with Paclitaxel and Carboplatin as first-line therapy in advanced non-small cell lung cancer. Clin Cancer Res 2008;14:1464-1469
82. Lalich M, McNeel DG, Wilding G, et al. Endothelin receptor antagonists in cancer therapy. Cancer Invest 2007;25:785-794 (Pubitemid 350223171)
83. Armstrong AJ, Creel P, Turnbull J, et al. A Phase I-II study of docetaxel and Atrasentan in men with castration-resistant metastatic prostate cancer. Clin Cancer Res 2008;14:6270-6276
84. Wynn TA. Cellular and molecular mechanisms of fibrosis. J Pathol 2008;214:199-210 •• An excellent review on the mechanisms of fibrosis.
85. Gauldie J, Bonniaud P, Sime P, et al. TGF-β, Smad3 and the process of progressive fibrosis. Biochem Soc Trans 2007;35:661-664
86. Clozel M, Salloukh H. Role of endothelin in fibrosis and anti-fibrotic potential of bosentan. Ann Med 2005;37:2-12 (Pubitemid 40347290)
87. Poncet S, Meyer S, Richard C, et al. The expression and function of the endothelin system in contractile properties of vaginal myofibroblasts of women with utero-vaginal prolapse. Am J Obst Gynecol 2005;192:426-432 (Pubitemid 40214975)
88. Antoniu SA. Targeting the endothelin pathway in the idiopathic pulmonary fibrosis: the role of bosentan. Exp Opin Ther Targets 2008;12:1077-1084
89. King TE. Bosentan for idiopathic pulmonary fibrosis. Curr Opin Invest Drugs 2008;9:1171-1179
90. Wenzel RR, Zbinden S, Noll G, et al. Endothelin-1 induces vasodilation in human skin by nociceptor fibres and release nitric oxide. Br J Clin Pharmacol 1998;45:441-446 (Pubitemid 28227344)
91. Vacca F, Bagnato A, Catt KJ, et al. Transactivation of the epidermal growth factor receptor in endothelin-1-induced mitogenic signaling in human ovarian carcinoma cells. Cancer Res 2000;60:5310-5317 (Pubitemid 30739794)
92. Michaelson MD, Kaufman DS, Oh WK, et al. Randomized Phase II study of atrasentan alone or in combination with zoledronic acid in men with metastatic prostate cancer. Cancer 2006;107:530-535 (Pubitemid 44107213)
93. Pirtskhalaishvili G, Nelson JB. Endothelium-derived factors as paracrine mediators of prostate cancer progression. Prostate 2000;44:77-87 (Pubitemid 30390068)
94. Barst RJ, Langleben D, Badesch D, et al. Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. J Am Coll Cardiol 2006;47:2049-2056
95. Galie N, Olschewski H, Oudiz RJ, et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 2008;117:3010-3019
96. Nelson JB. Endothelin receptor antagonists. World Urol J 2005;23:19-27
97. Carducci M, Padley RJ, Breu J, et al. The effect of endothelin A receptor blockade with Atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, placebo controlled, trial. J Clin Oncol 2003;21:679-689 (Pubitemid 46621903)
98. Carducci MA, Saad F, Abrahamsson PA, et al. A phase 3 randomized controlled trial on the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer. Cancer 2007;110:1959-1966 (Pubitemid 350036854)
99. James ND, Caty A, Borre M, et al. Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomized, phase 2 trial. Eur Urol 2009;55:1112-1123
100. Warren R, Liu G. ZD4054: a specific endothelin A receptor antagonist with promising activity in metastatic castration-resistant prostate cancer. Expert Opin Invest Drugs 2008;17:1237-1245